SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it completed patient enrollment in the
first of three planned Phase 3 pivotal trials evaluating the efficacy and
safety of its lead drug candidate, lorcaserin hydrochloride, for the treatment
of obesity. Known as BLOOM (Behavioral...
SAN DIEGO, Feb 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device
Conference on Wednesday, February 7, 2007 at 9:20 a.m. Eastern Time (6:20 a.m.
Pacific Time) at ...
SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced the completion of a public offering of
13,225,000 shares of its common stock at a public offering price of $13.21 per
share, including 1,725,000 shares sold pursuant to the full exercise of an
over-allotment option granted to the un...
SAN DIEGO, Dec 08, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today the pricing of its public offering of
11,500,000 shares of its common stock at a public offering price of $13.21 per
share. All of the shares are being offered by Arena. The underwriters have a
30-day option ...
SAN DIEGO, Nov. 28 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it plans to publicly offer 8,000,000
shares of its common stock pursuant to an effective registration statement
previously filed with the Securities and Exchange Commission. In connection
with this offering, Arena plans to grant ...
SAN DIEGO, Nov. 22 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present a
corporate overview and update of its clinical development and discovery
programs at two upcoming investor conferences:
Lazard Capital Markets Third Annual Life Scien...
SAN DIEGO, Nov 09, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it will host a Research and Development
Day on Thursday, November 9, 2006, beginning at approximately 12:00 p.m.
Eastern Time (9:00 a.m. Pacific Time). Jack Lief, President and Chief
Executive Officer, Do...
SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present a
corporate overview and update of its clinical development and discovery
programs at two upcoming investor conferences:
2006 Annual Stanford Growth Conference - Healthcar...
SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it will host a Research and Development
Day on Thursday, November 9, 2006, beginning at approximately 12:00 p.m.
Eastern Time (9:00 a.m. Pacific Time). Jack Lief, President and Chief
Executive Officer, Dominic P. Behan, Ph.D., Sen...
SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced it will report third quarter 2006 financial
results after the NASDAQ Global Market closes on Wednesday, October 25, 2006.
That same afternoon, Jack Lief, Arena's President and Chief Executive Officer,
and Robert E. Hoffman, Arena's Vic...
SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported financial results for the third quarter and nine
months ended September 30, 2006.
Total revenues in the third quarter of 2006 were $4.4 million, compared to
$7.4 million in the third quarter of 2005. Total revenues in the fi...
SAN DIEGO, Oct 18, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced it will report third quarter 2006 financial
results after the NASDAQ Global Market closes on Wednesday, October 25, 2006.
That same afternoon, Jack Lief, Arena's President and Chief Executive Officer,
and Rober...
SAN DIEGO, Oct. 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company will be presenting at the BIO
InvestorForum on Wednesday, October 18, 2006 at 12:20 p.m. Pacific Time
(3:20 p.m. Eastern Time) at the Palace Hotel in San Francisco. Louis Scotti,
Arena's Vice President, Marketing and ...
SAN DIEGO, Sept 27, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that Ortho-McNeil Pharmaceutical, Inc.
exercised its option to extend the research term for one additional year under
the provisions of its partnership with Arena to develop compounds targeting
the Glucose-Dep...
SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that an investigational niacin receptor agonist
that was being developed under its partnership with Merck & Co., Inc. to
develop drugs for the treatment of atherosclerosis and other disorders is no
longer in development for the tr...
SAN DIEGO, Sept. 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company will be presenting at two
upcoming investor conferences during which it is scheduled to provide a
corporate overview of the company and its clinical development and discovery
programs. The conference information is as...
SAN DIEGO, Sept. 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced the dosing of the first patient in the first of
three planned Phase 3 clinical trials evaluating the efficacy and safety of
its lead drug candidate, lorcaserin hydrochloride, for the treatment of
obesity. Known as BLOOM (Behavioral m...
SAN DIEGO, Sept. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company will be presenting at the Bear
Stearns 19th Annual Healthcare Conference on Tuesday, September 12, 2006 at
3:00 p.m. Eastern Time (12:00 p.m. Pacific Time) at the Grand Hyatt in New
York City. Jack Lief, Arena's Presid...
SAN DIEGO, Aug 14, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that Christine A. White, M.D. was appointed to
its board of directors. Dr. White is Arena's seventh independent director and
brings significant development and regulatory experience to its board.
Dr. ...
SAN DIEGO, July 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced it will report second quarter 2006 financial
results after the NASDAQ Global Market closes on Tuesday, July 25, 2006. That
same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and
Robert E. Hoffman, Arena's Vice P...
